Abstract
Based on existing data regarding the durability of liraglutide in type 2 diabetes, this study aimed to assess its long-term effectiveness at 5 years and its overall impact on cardiovascular (CV) risk. This was a multicenter retrospective observational study. Liraglutide was used under routine clinical practice conditions. Changes from baseline to 60 months in HbA1c, fasting plasma glucose (FPG), body weight, blood pressure, and lipid profile were assessed. United Kingdom Prospective Diabetes Study (UKPDS) scores were calculated at baseline and after 60 months to assess changes in the estimated 5- and 10-year risk for fatal and nonfatal coronary heart disease (CHD) and fatal and nonfatal stroke. Overall, 103 patients (age 59.0 ± 7.9 years, diabetes duration 10.4 ± 6.8 years) were involved in the study. After 60 months, HbA1c levels were reduced by - 1.0 ± 1.2%, FPG levels by - 24.5 ± 43.4 mg/dl, body weight by - 5.3 ± 6.4 kg, systolic blood pressure by - 6.5 ± 18.5 mmHg, diastolic blood pressure by - 3.6 ± 11.8 mmHg, and total cholesterol by - 16.9 ± 37.4 mg/dl. The proportion of patients achieving HbA1c levels of < 7% increased from 12.7% to 39.8% (p = 0.02). Based on the UKPDS scores, statistically significant reductions in t...Continue Reading
References
May 21, 1999·Archives of Internal Medicine·T M DavisR C Turner
Nov 14, 2006·Lancet·Daniel J Drucker, Michael A Nauck
Sep 30, 2008·Lancet·Alan GarberUNKNOWN LEAD-3 (Mono) Study Group
Oct 22, 2008·Diabetes Care·Michael NauckUNKNOWN LEAD-2 Study Group
Feb 3, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·J-P CourrègesS Madsbad
Mar 18, 2009·Diabetes Care·Bernard ZinmanUNKNOWN LEAD-4 Study Investigators
Mar 26, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·M MarreUNKNOWN LEAD-1 SU study group
May 26, 2009·JACC. Cardiovascular Interventions·Edward L Hannan
May 26, 2009·Lancet·Kausik K RayNaveed Sattar
Aug 19, 2009·Diabetologia·D Russell-JonesUNKNOWN Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group
Sep 3, 2011·Diabetes, Obesity & Metabolism·B ZinmanS Gough
Feb 1, 2012·Nature Reviews. Cardiology·Jacob SivertsenTina Vilsbøll
Jun 8, 2012·Experimental Diabetes Research·Matteo MonamiEdoardo Mannucci
Feb 25, 2014·Journal of Diabetes and Its Complications·Vivian A FonsecaJorge Plutzky
Jan 30, 2015·Clinical Therapeutics·Annunziata LapollaNatalino Simioni
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jun 28, 2016·Cell Metabolism·Daniel J Drucker
Jun 29, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Amrita OstawalWeiwei Xu
Dec 13, 2016·Clinical Therapeutics·Maurizio RondinelliStefano Genovese
Feb 1, 2017·Advances in Therapy·Luc MartinezPierre Gourdy
Oct 28, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Maja Cigrovski BerkovicTomislav Bozek
Dec 23, 2017·Advances in Therapy·Annunziata LapollaUNKNOWN NN2211-4118 Study Group
Citations
Oct 16, 2019·Clinical and Experimental Hypertension : CHE·Di ZhaoPingshuan Dong
Sep 22, 2020·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Mark P MaskeryHedley Ca Emsley
Jan 2, 2020·International Journal of Environmental Research and Public Health·Maria MirabelliAntonio Brunetti
Apr 4, 2021·Journal of Clinical Medicine·Maria MirabelliAntonio Brunetti